The Hsp70/Hsp90 molecular chaperone system represents a critical component of the cellular proteostasis network that is particularly relevant to Parkinson's Disease (PD) pathogenesis. These heat shock proteins coordinate protein folding, assembly of protein complexes, and targeting of misfolded proteins for degradation, thereby protecting neurons from the toxic effects of alpha-synuclein aggregation and other proteostatic stressors central to PD pathophysiology.
In PD, the chaperone system faces extraordinary challenges due to the progressive accumulation of misfolded alpha-synuclein, mitochondrial proteins damaged by oxidative stress, and endoplasmic reticulum stress resulting from cellular dysfunction. Understanding how Hsp70 and Hsp90 function—and how they fail—in dopaminergic neurons provides critical insights into disease mechanisms and therapeutic opportunities.
The HSP70 family encompasses multiple isoforms with distinct cellular localizations and functions in the brain:
- HSPA1A (Hsp70): Stress-inducible isoform highly upregulated under proteotoxic stress conditions
- HSPA8 (Hsc70): Constitutively expressed "constitutive" Hsp70 involved in protein folding and autophagy
- HSPA5 (GRP78/BiP): ER-resident chaperone critical for unfolded protein response regulation
- HSPA9 (mortalin/GRP75): Mitochondrial Hsp70 involved in protein import and mitochondrial quality control
- HSP90AA1: Cytosolic, stress-inducible isoform
- HSP90AB1: Cytosolic, constitutively expressed "β" isoform
- HSP90B1 (GRP94): ER-resident isoform
- HSP90 (mitochondrial): Distinct mitochondrial isoform involved in protein import
Hsp70 and Hsp90 directly interact with alpha-synuclein at multiple stages of the aggregation process:
Nucleation Phase Suppression:
- Hsp70 binds to soluble alpha-synuclein monomers, preventing conformational transitions that initiate aggregation
- The J-domain protein DNAJB1 specifically recognizes oligomeric alpha-synuclein intermediates through multivalent interactions, targeting the Hsp70 machinery to toxic oligomers
Fibril Disassembly:
- The Hsp70 disaggregation machinery (Hsc70-DNAJB1-HSP110) can reverse alpha-synuclein amyloid fibrils back to soluble monomers through a mechanism where monomer units are removed directly from fibril ends
- This activity demonstrates that amyloid fibrils are not irreversible endpoints but can be disassembled by the endogenous chaperone system
The specificity and activity of Hsp70 toward alpha-synuclein is regulated by co-chaperones:
- J-domain proteins (DNAJA1, DNAJB1, DNAJC12): Deliver misfolded substrates to Hsp70; DNAJB1 shows particular specificity for alpha-synuclein oligomers
- NEFs (HSP110, BAG1-6): Regulate nucleotide exchange and substrate release kinetics
- Hsp40/Hsp70 complexes: Form the primary machinery for alpha-synuclein clearance in neurons
flowchart TD
Aα-Synuclein["Aα-Synuclein Monomers"] --> B{"Hsp70/Hsp90 Activity"}
B -->|"Sufficient"| C["Native Folding"]
B -->|"Insufficient"| D["Oligomerization"]
D --> E["Fibril Formation"]
D --> F["Toxic Oligomers"]
C --> G["Normal Synaptic Function"]
E --> H["Lewy Body Formation"]
F --> I["Neuronal Dysfunction"]
J["Hsp70 System"] --> K["Substrate Binding"]
K --> L["ATP Hydrolysis"]
L --> M["Refolding or Degradation"]
M --> N["Proteasome"]
M --> O["Autophagy"]
style J fill:#c8e6c9
style K fill:#c8e6c9
style L fill:#c8e6c9
¶ ER Stress and the Unfolded Protein Response
The endoplasmic reticulum represents a critical site of proteostatic stress in PD dopaminergic neurons. Key ER chaperones include:
- HSPA5 (GRP78/BiP): The master ER chaperone that regulates the unfolded protein response
- ERdj proteins (DNAJB9, DNAJC3): ER-resident J-domain proteins coordinating protein folding
- Calnexin/Calreticulin: Calcium-dependent chaperones affected in PD
ER stress activates the unfolded protein response (UPR), which attempts to restore ER homeostasis through:
- Attenuation of protein translation
- Upregulation of ER chaperones including Hsp70 family members
- Activation of ER-associated degradation (ERAD)
In PD, chronic ER stress leads to persistent UPR activation, ultimately triggering apoptotic pathways in dopaminergic neurons. The failure of adaptive UPR responses contributes to neurodegeneration.
¶ Mitochondrial Protein Import and Quality Control
The mitochondrial Hsp70 system, also known as mortalin (HSPA9), plays essential roles in PD:
- Protein import: Facilitates translocation of nuclear-encoded mitochondrial proteins across the inner mitochondrial membrane
- Mitochondrial protein folding: Assists in proper folding of imported proteins in the mitochondrial matrix
- Quality control: Identifies and targeting misfolded mitochondrial proteins for degradation
The PINK1/Parkin mitophagy pathway intersects with the chaperone system:
- Damaged mitochondria accumulate PINK1 on the outer membrane
- Parkin recruitment triggers ubiquitination of mitochondrial proteins
- The chaperone system participates in recognizing and processing damaged mitochondrial proteins for autophagic clearance
Mutations in PINK1 (PARK6) and PARKIN (PARK2) cause early-onset familial PD, highlighting the critical importance of mitochondrial quality control.
In PD, mitochondrial chaperone function is compromised through:
- Oxidative damage to Hsp70/Hsp90 proteins
- Decreased expression of mitochondrial Hsp70
- Impaired protein import leading to accumulation of misfolded mitochondrial proteins
The proteostasis network in neurons comprises interconnected systems:
| System |
Key Components |
Function in PD |
| Molecular chaperones |
Hsp70, Hsp90, sHsp |
Protein folding, aggregation prevention |
| Ubiquitin-proteasome |
26S proteasome, E3 ligases |
Targeted protein degradation |
| Autophagy-lysosomal |
Macroautophagy, CMA |
Bulk protein clearance |
| Chaperone-mediated autophagy |
Hsc70, LAMP-2A |
Selective protein turnover |
The chaperone system becomes progressively overwhelmed in PD:
- Early stage: Compensatory upregulation of chaperones attempts to handle increased alpha-synuclein load
- Intermediate stage: Chaperone capacity is exceeded; toxic oligomers accumulate
- Late stage: Chaperone system itself may be recruited into Lewy bodies, rendering it non-functional
This progression explains the relative preservation of neurons early in disease and the acceleration of pathology once compensatory mechanisms fail.
The chaperone system intersects with multiple PD-relevant pathways:
- LRRK2 pathway: LRRK2 kinase activity affects chaperone function; G2019S mutation increases chaperone burden
- GBA pathway: Glucocerebrosidase deficiency impairs lysosomal function, increasing reliance on cytosolic chaperone clearance
- Mitochondrial dysfunction: Chaperones protect against mitochondrial protein damage
- Ubiquitin-proteasome system: Chaperones target proteins for proteasomal degradation
Pharmacological upregulation of Hsp70 represents a promising therapeutic strategy:
- Geldanamycin derivatives: Natural products that inhibit Hsp90 and induce Hsp70 expression
- Synthetic Hsp70 inducers: Small molecules targeting HSF1 (heat shock factor 1) activation
- Natural compounds: Curcumin, geranylgeranylacetone stimulate Hsp70 expression
Hsp90 inhibitors paradoxically provide neuroprotection through dual mechanisms:
- Destabilization of client proteins including mutant LRRK2 and tau
- Compensatory upregulation of Hsp70 and other protective chaperones
Emerging approaches target multiple components of the proteostasis network:
- Hsp70 + autophagy enhancers: Synergistic enhancement of protein clearance
- Small molecule chaperones: Pharmacological chaperones that assist protein folding
- Gene therapy: Viral delivery of chaperone genes to enhance neuronal protection
¶ Synaptic Proteostasis and Neuroprotection
The synapse represents a critical site of proteostatic challenge in PD:
- High energy demand and protein turnover
- Distance from soma limits chaperone access
- Synaptic activity generates reactive oxygen species
- Alpha-synuclein localizes to presynaptic terminals
Synaptic dysfunction occurs early in PD:
- Loss of synaptic proteins precedes neuron loss
- Hsp70 protects against synuclein-induced synaptic damage
- Mitochondrial chaperones maintain synaptic energy
Dopaminergic neurons have unique proteostatic challenges:
- High metabolic demand with mitochondrial stress
- Sustained pacemaking calcium influx
- Neuromelanin accumulation with age
- Long axonal projections requiring distant protein quality control
Astrocytes support neuronal proteostasis through:
- Secretion of Hsp70 and Hsp90
- Support of extracellular chaperone pools
- Clearance of extracellular alpha-synuclein
- Cross-talk with neurons via chaperone signaling
Microglial chaperones in PD:
- Inflammatory activation alters chaperone expression
- Hsp70 released as damage-associated molecular pattern (DAMP)
- Extracellular Hsp70 can promote neuroinflammation
- Modulation of microglial proteostasis as therapeutic target
HSF1 is the master transcriptional regulator of chaperone expression:
- Trimerization and nuclear translocation under stress
- Binding to heat shock elements (HSE) in chaperone gene promoters
- Transcriptional activation of Hsp70, Hsp90, and co-chaperones
- Negative regulation by Hsp70/Hsp90 complexes
Strategies for HSF1 activation in PD:
- Geldanamycin/17-AAG: Hsp90 inhibition releases HSF1
- HSF1 agonists: Direct activation of HSF1 transcriptional activity
- Geranylgeranylacetone: FDA-approved Hsp70 inducer
- Natural compounds: Curcumin, sulforaphane activate HSF1
HSF1 activation in dopaminergic neurons:
- Protects against MPTP and 6-OHDA toxicity
- Reduces alpha-synuclein aggregation
- Enhances mitochondrial function
- Promotes autophagy-lysosomal pathway activity
DNAJ (Hsp40) co-chaperones provide substrate specificity:
- DNAJA1 (Hsp40): Broad substrate recognition
- DNAJB1: Strong preference for alpha-synuclein oligomers
- DNAJC12: Neuron-specific expression
- DNAJB6/B8: Anti-aggregation activity in neurons
¶ DNAJB1 and Alpha-Synuclein
DNAJB1 shows remarkable specificity:
- Recognizes oligomeric alpha-synuclein intermediates
- Targets toxic species for Hsp70-mediated clearance
- Prevents fibril propagation
- Mutations in DNAJB6 linked to PD risk
CMA selectively degrades proteins with KFERQ motif:
- Recognition by Hsc70 (HSPA8)
- LAMP-2A-mediated translocation into lysosome
- Direct degradation in lysosomal lumen
- Critical for alpha-synuclein turnover
CMA is impaired in PD through multiple mechanisms:
- LAMP-2A levels decrease with age
- Alpha-synuclein mutations impair CMA recognition
- Oxidative damage to CMA components
- GBA mutations disrupt lysosomal function
Therapeutic approaches to restore CMA:
- LAMP-2A overexpression in animal models
- Pharmacological CMA activation
- Combination with Hsp70 inducers
- Gene therapy approaches
¶ LRRK2 and Chaperone Interactions
¶ LRRK2 Mutations and Proteostasis
The relationship between LRRK2 and chaperones is complex:
- G2019S mutation increases chaperone burden
- LRRK2 kinase activity affects protein quality control
- Chaperone levels correlate with LRRK2 toxicity
- Hsp90 stabilizes mutant LRRK2
Targeting LRRK2-chaperone axis:
- Hsp90 inhibitors reduce mutant LRRK2 levels
- Hsp70 inducers may compensate for increased burden
- Combination approaches target multiple pathways
¶ GBA Mutations and Chaperone Dysfunction
GBA mutations are the most common genetic risk factor:
- Glucocerebrosidase deficiency impairs lysosomal function
- Alpha-synuclein accumulation in lysosomes
- Increased reliance on cytosolic chaperone clearance
- Chaperone system becomes overwhelmed
Therapeutic strategies:
- Pharmacological chaperones for GBA
- Hsp70 upregulation to compensate
- Autophagy enhancement
- Combination approaches
Hsp70 levels have diagnostic value:
- Cerebrospinal fluid Hsp70 elevated in PD
- Correlates with disease severity
- May predict progression
- Utility in differential diagnosis
Hsp70 as biomarker:
- Disease progression monitoring
- Therapeutic response assessment
- Subtype identification
- Combination with other markers
Gene therapy offers sustained chaperone expression:
- AAV vectors for Hsp70 delivery
- Targeted delivery to substantia nigra
- Demonstrated safety in preclinical models
- Translation to clinical trials
Targeting specific cell populations:
- Neuron-specific promoters
- Microglial-targeted delivery
- Astrocytic expression strategies
- Optimized vector design
Aging impairs proteostasis:
- Hsp70 expression declines with age
- HSF1 activation becomes less efficient
- Accumulation of damaged proteins
- Reduced autophagy capacity
Age as risk factor:
- Chaperone decline predisposes to PD
- Therapeutic targeting of age-related changes
- Preventive strategies
- Early intervention potential
¶ Mitophagy and Chaperones
The intersection of chaperones and mitophagy:
- Hsp90 binds to damaged mitochondria
- Parkin recruitment requires chaperone function
- PINK1 stability depends on chaperones
- Therapeutic enhancement of mitophagy
Combined approaches:
- Hsp90 inhibitors enhance mitophagy
- Hsp70 inducers promote mitochondrial quality control
- Small molecule activators of PINK1/Parkin
- Autophagy enhancers
Alpha-synuclein oligomers as therapeutic target:
- DNAJB1 preferentially recognizes oligomers
- Hsp70-based clearance strategies
- Small molecule disruptors
- Antibody approaches
Therapeutic exploitation:
- Hsp70 disaggregase activity
- DNAJ co-chaperone enhancement
- Combination with small molecules
- Immunotherapy combinations
Multiple biotechnology companies are developing therapies targeting the HSP70/HSP90 chaperone system for Parkinson's disease:
- heqIX Therapeutics — Developing Hsp90 inhibitors and Hsp70 inducers for PD (HQX-101 in Phase 1)
- Iduna Therapeutics — Developing HSP70 modulators to enhance alpha-synuclein clearance (IDN-001 in IND-enabling studies)
- Spin Therapeutics — Developing protein disaggregation therapies targeting alpha-synuclein aggregates
heqIX Therapeutics focuses on heat shock protein modulation for neurodegenerative diseases. Their lead program HQX-101 is a brain-penetrant Hsp90 inhibitor that induces Hsp70 expression and promotes clearance of toxic alpha-synuclein aggregates. Phase 1 clinical trials completed in 2024[@heqix_corp].
Iduna Therapeutics develops small molecule chaperone modulators targeting the HSP70/HSP90 system. Their lead candidate IDN-001 directly enhances HSP70 activity to promote alpha-synuclein clearance. The company is conducting IND-enabling studies with anticipated Phase 1 initiation in 2026[@iduna-website].
Spin Therapeutics takes a complementary approach, developing small molecules that directly disaggregate alpha-synuclein fibrils and oligomers. While not directly targeting the chaperone system, their disaggregation approach works synergistically with the cellular proteostasis network to clear pathological aggregates.